Servier Canada, the Canadian subsidiary of the Servier Research Group, with the support of Montréal International (MI), Laval Technopole, the Biotech City, Montréal InVivo and Investissement Québec are together committing $16.3 million to construct a new Centre of Excellence in Clinical Research into cardiovascular disease, cancer and neuropsychiatry in Laval, QC.
The announcement was made in the presence of Nicolas Marceau, Québec Minister of Finance and the Economy, who confirmed the awarding of a $1-million nonrefundable financial contribution to launch the project. The new 30,000 square-foot complex will enable the company to hire forty or so new employees over the next few months.
“The Servier Research Group, the second largest French pharmaceutical company, decided to bolster its research endeavours in Canada, particularly in Québec, since the level of excellence in the research sector make it an ideal location to advance therapeutic innovation,” stated Emmanuel Canet, president of Servier R&D.
“Health is a priority issue. Our mission is to make available to the medical profession and Canadian patients the best possible therapeutic solutions. In order to achieve this, we must not only bolster our research efforts, but also benefit from a health policy that supports innovation,” added Frédéric Fasano, CEO of Servier Canada.
The Biotech City, site of the new centre of clinical research, is already home to a university (INRS), research laboratories, a business incubator and major biotechnology and biopharmaceutical companies.
“We have supported this leading Biotech City company throughout the entire project. Servier Canada is part of a dynamic business centre that houses, within a four-kilometre radius, basic research, clinical trials, production and marketing,” commented Pierre Desroches, president and executive director of Laval Technopole and the Biotech City of Laval.
The centre will house activities for the Canadian International Centre for Therapeutic Research (ICTR) and the Servier Canada National Centre for Professional Training. Its mandate will be to help further the design and development of ICTR clinical research in major therapeutic areas including cardiovascular disease, cancer and neuropsychiatry.
Leave a Reply